February 6, 2019

The Early Diagnosis of Alzheimer’s Disease: A Patient-centered Conversation with the Care Team

Virtual 2021 European Academy of Neurology (EAN) Congress

Clinical Assessment Tools to Evaluate a Memory Complaint

Ziad Nasreddine, MD, FRCP(C), provides his insights on the case study’s cognitive assessments and highlights the presence of some ‘red flags’ in the results. He outlines his approach for evaluating memory complaints in clinical practice and how various clinical assessment tools can be used at different points in the AD continuum. Dr. Nasreddine then describes the Montreal Cognitive Assessment (MoCA) in detail, including the diagnostic accuracy of the scale and recommended follow up.

Professor Frisoni provides further details from the case study, including fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging, cerebrospinal fluid (CSF) analysis, and amyloid and tau PET results.

Key Learning Objectives from Biogen’s EAN 2021 Symposium:

  • Address the complexities around diagnosis and management of AD, including how cognitive and functional assessments may support the early diagnosis of AD
  • Gain insights into the use of diagnostic biomarkers and the impact these could have on the patient journey
  • Discuss current and prospective measures that could be undertaken to allow the timely diagnosis and management of individuals with AD, in the context of current healthcare infrastructure

Disclosure: All panelists received honoraria from Biogen for participation in this symposium.

Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.